Communication between multiple drug binding sites on P-glycoprotein

Molecular Pharmacology

Volumn 58, Issue 3, 2000, Pages 624-632

  Martin, Catherine ^a   Berridge, Georgina ^a   Higgins, Christopher F ^b   Mistry, Prakash ^c   Charlton, Peter ^c   Callaghan, Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRANILIC ACID DERIVATIVE; CYTOTOXIC AGENT; ELACRIDAR; GLYCOPROTEIN P; HOE 33342; NICARDIPINE; PACLITAXEL; PIPERAZINEDIONE; RADIOLIGAND; RHODAMINE 123; TARIQUIDAR; TRITIUM; UNCLASSIFIED DRUG; VINBLASTINE; XR 9051;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CHO CELL; CYTOTOXICITY; DRUG BINDING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL;

EID: 0033862765     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.58.3.624     Document Type: Article

References (40)

1. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
2. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein
3. Two different regions of phosphoglycoprotein are photoaffinity labeled by azidopine
4. Structural requirements for activity of propafenone-type modulators in P-glycoprotein mediated multidrug resistance
5. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative
6. Evidence for two non-identical drug-interaction sites in human P-glycoprotein
7. The importance of a nitrogen atom in modulators of multidrug resistance
8. Testing the role of P-glycoprotein expression in clinical trials: Applying pharmacological principles and best methods for detection together with good clinical trials methodology
9. P-glycoprotein possesses a 1,4-dihydropyridine selective drug acceptor site which is allosterically coupled to a vinca alkaloid selective binding site
10. 125I]iodipine
11. 2+ channel by photoaffinity labeling
12. Biochemistry of multidrug resistance by the multidrug transporter
13. Major photoaffinity labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within or immediately C-terminal to transmembrane domains 6 and 12
14. Domain mapping of the photoaffinity drug binding sites in P-glycoprotein encoded by mouse mdr 1b
15. + channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: Opposite effects of MgADP
16. Fluorescent cellular indicators are extruded by the multidrug resistance protein
17. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
18. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
19. + gradient stimulated uptake
20. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains
21. 3H]vinblastine binding to P-glycoprotein of CCRF ADR5000 cells
22. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction
23. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein
24. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity
25. Localization of the forskolin labeling sites to both halves of P-glycoprotein: Similarity of the sites labeled by forskolin and prazosin
26. Effects of steroids and verapamil on P-glycoprotein ATPase activity: Progesterone, desoxycorticosterone and verapamil are mutually non-exclusive modulators
27. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents
28. Photosensitized labeling of a functional multidrug transporter in living drug resistant tumor cells
29. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter
30. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third binding site
31. Positively cooperative sites for drug transport by P-glycoprotein with specific drug specificities
32. Secondary and tertiary structure changes of reconstituted P-glycoprotein. A Fourier transform attenuated total reflection infrared spectroscopy analysis
33. Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein
34. Dissection of drug-binding-induced conformational changes in P-glycoprotein
35. The genetic basis of resistance to cancer chemotherapy
36. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells